tbuckley/cabot-search huggingface dataset:
Degradable Alginate Hydrogel Intervention Catheters with Gradient Hardness in Length
Authors: Bingbing Yang, Weinan Gu, Jie Pan, Lidong Zhang
Journal: Advanced Healthcare Materials (2025)

Abstract Interventional catheter, a medical device characterized by a gradient hardness from one end to the other, exhibits enhanced flexibility upon insertion into the human body. This unique configuration accommodates various anatomical structures and surgical requirements. This study reports, for the first time, a degradable hydrogel interventional catheter with gradient hardness. A novel aqueous reaction methodology is developed, enabling the direct transformation of a solid sodium alginate (SA) film strip into a hollow hydrogel interventional catheter. This process involves copper ions‐induced asymmetry crosslinking in an aqueous solution, solvent exchange in ethanol, removal of copper ions by ethylenediaminetetraacetic acid, and subsequent bimetallic crosslinking in CaCl 2 and FeCl 3 aqueous solutions. This method results in gradient‐hardness hydrogel interventional catheters without surface defects such as protrusions and pits. The hydrogel interventional catheter demonstrates gradient robustness with mechanical strength reaching 5.5 MPa for the soft head and 28 MPa for the hard tail. By incorporating a gradual stiffness variation, the hydrogel catheter with superior lubricity and flexibility more effectively adapts to the anatomical structures of the human body, potentially minimizing tissue damage and expediting surgical procedures. Consequently, it shows significant potential as a medical interventional catheter.
Molybdenum Disulfide Nanocomposites for Cancer Diagnosis and Therapeutics: Biosensors, Bioimaging, and Phototherapy
Authors: Fatemeh Sasanipoor, Zhiqing Zhang
Journal: Advanced Healthcare Materials (2025)

Abstract Molybdenum disulfide (MoS₂) nanomaterials have attracted significant interest in cancer diagnosis and therapy due to their unique physicochemical properties. Due to its extensive surface area and adaptable structure, MoS₂ may engage with pharmaceuticals and biomolecules via covalent and non‐covalent interactions. This versatility enhances the sensitivity of identifying specific biomarkers, colloidal stability, and tumor‐targeting capabilities. In the near‐infrared (NIR) spectrum, MoS₂ exhibits strong optical absorption and efficient photothermal conversion, making it suitable for NIR‐driven phototherapy and regulated medication release. Functionalized MoS₂ nanocomposites react differently to the tumor microenvironment, which improves treatment effectiveness by increasing drug accumulation at cancer sites and decreasing off‐target effects on healthy tissues. Recent developments in MoS₂‐based nanocomposites for cancer detection and treatment are reviewed in this study, with particular attention paid to their uses in photothermal therapy, photodynamic therapy, biosensing, and bioimaging. Additionally, it looks at the difficulties and potential applications of MoS₂ nanocomposites in cancer.
Suppression of the Prostaglandin I2–Type 1 Interferon Axis Induces Extramedullary Hematopoiesis to Promote Cardiac Repair After Myocardial Infarction
Authors: Huizhen Lv, Chenchen Wang, Zening Liu, Meixi Quan, Kan Li, Fanglin Gou, Xuelian Shi, Qian Liu, Ying Yu, Ping Zhu, Hui Cheng, Tao Cheng, Ding Ai
Journal: Circulation (2025)

BACKGROUND: Immune cells are closely associated with all processes of cardiac repair after myocardial infarction (MI), including the initiation, development, and resolution of inflammation. Spleen extramedullary hematopoiesis (EMH) serves as a crucial source of emergency mature blood cells that are generated through the self-renewal and differentiation of hematopoietic stem/progenitor cells (HSPCs). However, how EMH responds to MI and the role of EMH in cardiac repair after MI remains unclear. METHODS: To assess the role of spleen EMH in MI, a Tcf21 CreER Scf flox/flox MI mouse model with inhibited EMH was constructed. GFP + (green fluorescent protein) hematopoietic stem cells were sorted from eGFP (enhanced green fluorescent protein) mouse spleen by flow cytometry and injected into Tcf21 CreER Scf flox/flox mice to test the sources of local inflammatory cells during MI. Using highly specific liquid chromatography–tandem mass spectrometry and single-cell RNA sequencing, we analyzed the lipidomic profile of arachidonic acid metabolites and the transcriptomes of HSPCs in the spleen after MI. RESULTS: We found that MI enhanced EMH, as reflected by the increase in spleen weight and volume and the number of HSPCs in the spleen. The lack of EMH in Scf -deficient mice exacerbated tissue injury after MI. Analysis of the transcriptome of spleen HSPCs after MI revealed that the type 1 interferon pathway was substantially inhibited in hematopoietic stem cell/multipotent progenitor subclusters, and the absence of type 1 interferon signaling enhanced the MI-induced spleen EMH. Lipidomics analysis revealed that prostaglandin I2 (PGI2) was markedly reduced in the spleen. PGI2 suppressed MI-induced EMH through a PGI2 receptor (IP)–cyclic adenosine monophosphate– 453 p-SP1 cascade in spleen HSPCs. Hematopoietic cell–specific IP-deficient mice exhibited enhanced EMH and improved cardiac recovery after MI. CONCLUSIONS: Together, our findings revealed that a PGI2–IFN axis was involved in spleen EMH after MI, providing new mechanistic insights into spleen EMH after MI and offering a new therapeutic target for treating ischemic cardiac injury.
Medieval genomes from eastern Iberia illuminate the role of Morisco mass deportations in dismantling a long-standing genetic bridge with North Africa
Authors: Gonzalo Oteo-Garcia, Marina Silva, M George B Foody, Bobby Yau, Alessandro Fichera, Llorenç Alapont, Pierre Justeau, Simão Rodrigues, Rita Monteiro, Francesca Gandini, María Luisa Rovira Gomar, Albert Ribera I Lacomba, Josep Pascual Beneyto, Valeria Mattiangeli, Daniel G Bradley, Ceiridwen J Edwards, Maria Pala, Martin B Richards
Journal: Genome biology (2025)

Abstract Background The Islamic influence on the Iberian Peninsula left an enduring cultural and linguistic legacy. However, the demographic impact is less well understood. This study aims to explore the dynamics of gene flow and population structure in eastern Iberia from the early to late medieval period through ancient DNA. Results Our comprehensive genomic analysis uncovers gene flow from various Mediterranean regions into Iberia before the Islamic period, supporting a pre-existing pan-Mediterranean homogenization phenomenon during the Roman Empire. North African ancestry is present but sporadic in late antiquity genomes but becomes consolidated during the Islamic period. We uncover one of the earliest dated Islamic burials in Spain, which shows high levels of consanguinity. For the first time, we also demonstrate the persistence of North African ancestry in a Christian cemetery until the seventeenth century, in addition to evidence of slave trafficking from North Africa. Conclusions This study reveals the complex interaction between political events and cultural shifts that influenced the population of eastern Iberia. It highlights the existence of a slave trade, underscores the low impact of the Reconquista in the genetic landscape, and shows the lasting impact of post-medieval events, such as the Expulsion of the Moriscos in 1609 CE, on the region’s genetic and cultural landscape, through mass population displacement and replacement.
Oryza genome evolution through a tetraploid lens
Authors: Alice Fornasiero, Tao Feng, Noor Al-Bader, Aseel Alsantely, Saule Mussurova, Nam V Hoang, Gopal Misra, Yong Zhou, Leonardo Fabbian, Nahed Mohammed, Luis Rivera Serna, Manjula Thimma, Victor Llaca, Praveena Parakkal, David Kudrna, Dario Copetti, Shanmugam Rajasekar, Seunghee Lee, Jayson Talag, Chandler Sobel-Sorenson, Marie-Christine Carpentier, Olivier Panaud, Kenneth L McNally, Jianwei Zhang, Andrea Zuccolo, M Eric Schranz, Rod A Wing
Journal: Nature Genetics (2025)

Oryza is a remarkable genus comprising 27 species and 11 genome types, with ~3.4-fold genome size variation, that possesses a virtually untapped reservoir of genes that can be used for crop improvement and neodomestication. Here we present 11 chromosome-level assemblies (nine tetraploid, two diploid) in the context of ~15 million years of evolution and show that the core Oryza (sub)genome is only ~200 Mb and largely syntenic, whereas the remaining nuclear fractions (~80-600 Mb) are intermingled, plastic and rapidly evolving. For the halophyte Oryza coarctata, we found that despite detection of gene fractionation in the subgenomes, homoeologous genes were expressed at higher levels in one subgenome over the other in a mosaic form, demonstrating subgenome equivalence. The integration of these 11 new reference genomes with previously published genome datasets provides a nearly complete view of the consequences of evolution for genome diversification across the genus.
Natural Killer T Cells Link Stress Hyperglycemia to Cognitive Decline in HFpEF
Authors: Pasquale Mone, Michele Ciccarelli, Stanislovas S. Jankauskas, Francesca Picone, Germano Guerra, Gianluca Testa, Francesco Moccia, Roberto Magliuolo, Marco Di Mauro, Antonio De Luca, Albino Carrizzo, Carmine Vecchione, Gaetano Santulli
Journal: Circulation Research (2025)
Splenic CD169 <sup>+</sup> Tim4 <sup>+</sup> Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction
Authors: Mohamed Ameen Ismahil, Guihua Zhou, Shreya Rajasekar, Min Gao, Shyam S. Bansal, Bindiya Patel, Nita Limdi, Min Xie, Sergey Antipenko, Gregg Rokosh, Tariq Hamid, Sumanth D. Prabhu
Journal: Circulation (2025)

BACKGROUND: Fidelity of wound healing after myocardial infarction (MI) is an important determinant of subsequent adverse cardiac remodeling and failure. Macrophages derived from infiltrating Ly6C hi (lymphocyte antigen 6 complex, locus C) blood monocytes are a key component of this healing response; however, the importance of other macrophage populations is unclear. METHODS: We used a variety of in vivo murine models and orthogonal approaches, including surgical MI, flow cytometry and single-cell RNA sequencing, lineage tracing and cell tracking, splenectomy, parabiosis, cell adoptive transfer, and functional characterization, to establish an essential role for splenic CD169 + Tim4 + (cluster of differentiation 169 + ; T cell immunoglobulin– and mucin-domain–containing molecule 4) marginal metallophilic macrophages (MMMs) in post-MI wound healing in mice. Flow cytometry was used to measure circulating CD169 + Tim4 + monocytes in humans with ST-segment–elevation MI and control participants with stable coronary artery disease undergoing elective percutaneous coronary intervention. RESULTS: Splenic CD169 + Tim4 + MMMs circulate in blood as Ly6C low monocytes expressing macrophage markers and help populate CD169 + Tim4 + CCR2 − LYVE1 low macrophages in the naive heart. After acute MI, splenic MMMs augment phagocytosis and CCR (C-C motif chemokine receptor) 3 and CCR4 expression, and robustly mobilize to the heart, resulting in marked expansion of cardiac CD169 + Tim4 + LYVE1 low macrophages with an immunomodulatory and proresolving gene signature. These macrophages are obligatory for apoptotic neutrophil clearance, suppression of inflammation, and induction of a reparative macrophage phenotype in the infarcted heart. Splenic MMMs are both necessary and sufficient for post-MI wound healing, and limit late pathological remodeling. Liver X receptor-α agonist–induced expansion of the splenic marginal zone and MMMs during acute MI alleviates inflammation and improves short- and long-term cardiac remodeling. Humans with acute ST-segment–elevation MI also exhibit expansion of circulating CD169 + Tim4 + cells, primarily within the intermediate (CD14 + CD16 + ) monocyte population. CONCLUSIONS: Splenic CD169 + Tim4 + MMMs are required for proresolving and reparative responses after MI and can be manipulated for therapeutic benefit to limit long-term heart failure.
Rewiring of SINE-MIR enhancer topology and Esrrb modulation in expanded and naive pluripotency
Authors: Nadia Omega Cipta, Yingying Zeng, Ka Wai Wong, Zi Hao Zheng, Yao Yi, Tushar Warrier, Jian Zhou Teo, Jia Hao Jackie Teo, Yee Jiun Kok, Xuezhi Bi, Reshma Taneja, Derrick Sek Tong Ong, Jian Xu, Florent Ginhoux, Hu Li, Yih-Cherng Liou, Yuin-Han Loh
Journal: Genome biology (2025)

The interplay between 3D genomic structure and transposable elements (TE) in regulating cell state-specific gene expression program is largely unknown. Here, we explore the utilization of TE-derived enhancers in naïve and expanded pluripotent states by integrative analysis of genome-wide Hi-C-defined enhancer interactions, H3K27ac HiChIP profiling and CRISPR-guided TE proteomics landscape. We find that short interspersed nuclear elements (SINEs) are the more involved TEs in the active chromatin and 3D genome architecture. In particular, mammalian-wide interspersed repeat (MIR), a SINE family member, is highly associated with naïve-specific genomic interactions compared to the expanded state. Primarily, in the naïve pluripotent state, MIR enhancer is co-opted by ESRRB for naïve-specific gene expression program. This ESRRB and MIR enhancer interaction is crucial for the formation of loops that build a network of enhancers and super-enhancers regulating pluripotency genes. We demonstrate that loss of a ESRRB-bound MIR enhancer impairs self-renewal. We also find that MIR is co-bound by structural protein complex, ESRRB-YY1, in the naïve pluripotent state. Altogether, our study highlights the topological regulation of ESRRB on MIR in the naïve potency state.
Multi-ancestry whole genome sequencing analysis of lean body mass
Authors: Xiaoyu Zhang, Kuan-Jui Su, Bodhisattwa Banerjee, Ittai Eres, Yi-Hsiang Hsu, Carolyn J Crandall, Rajashekar Donaka, Zhe Han, Rebecca D Jackson, Hanhan Liu, Zhe Luo, Braxton D Mitchell, Chuan Qiu, Qing Tian, Hui Shen, Ming-Ju Tsai, Kerri L Wiggins, Hanfei Xu, Michelle Yau, Lan-Juan Zhao, Xiao Zhang, May E Montasser, Douglas P Kiel, Hong-Wen Deng, Ching-Ti Liu, David Karasik
Journal: Genome biology (2025)

Lean body mass is a crucial physiological component of body composition. Although lean body mass has a high heritability, studies evaluating the genetic determinants of lean mass (LM) have to date been limited largely to genome-wide association studies (GWAS) and common variants. Using whole genome sequencing (WGS)-based studies, we aimed to discover novel genetic variants associated with LM in population-based cohorts with multiple ancestries. We describe the largest WGS-based meta-analysis of lean body mass to date, encompassing 10,729 WGS samples from six TOPMed cohorts and the Louisiana Osteoporosis Study (LOS) cohort, measured with dual-energy X-ray absorptiometry. We identify seven genome-wide loci significantly associated with LM not reported by previous GWAS. We partially replicate these associations in UK Biobank samples. In rare variant analysis, we discover one novel protein-coding gene, DMAC1, associated with both whole-body LM and appendicular LM in females, and a long non-coding RNA gene linked to appendicular LM in males. Both genes exhibit notably high expression levels in skeletal muscle tissue. We investigate the functional roles of two novel lean-mass-related genes, EMP2 and SSUH2, in animal models. EMP2 deficiency in Drosophila leads to significantly reduced mobility without altering muscle tissue or body fat morphology, whereas an SSUH2 gene mutation in zebrafish stimulates muscle fiber growth. Our comprehensive analysis, encompassing a large-scale WGS meta-analysis and functional investigations, reveals novel genomic loci and genes associated with lean mass traits, shedding new insights into pathways influencing muscle metabolism and muscle mass regulation.
Establishing the content validity of Patient-Reported Outcome measures used in neuro-oncology based on the WHO ICF framework: part of the RANO-PRO initiative
Authors: Ogechukwu A Asogwa, Linda Dirven, Tobias Walbert, Terri S Armstrong, David Arons, Martin J van den Bent, Jaishri Blakeley, Marijke B Coomans, Paul D Brown, Helen Bulbeck, Susan M Chang, Corneel Coens, Mark R Gilbert, Robin Grant, Rakesh Jalali, Johan A F Koekkoek, Pankaj Kumar Panda, Danielle Leach, Heather Leeper, Tito Mendoza, Lakshmi Nayak, Kathy Oliver, Jaap C Reijneveld, Emilie Le Rhun, Larry Rubinstein, Jennie W Taylor, Michael Weller, Patrick Y Wen, Martin J B Taphoorn
Journal: Neuro-Oncology (2025)

Abstract Background Instruments to assess patient-reported outcomes (PRO) should generate high-quality evidence. Reliable PRO evidence is essential to policymakers, in conjunction with outcomes such as survival and radiological response, to understand the net clinical benefit of antitumor treatments. This study aimed to establish the content validity of 215 identified PRO measures used in patients with brain tumors. Methods A survey (n = 148 items) was developed reflecting aspects of the WHO International Classification of Functioning, Disability, and Health (ICF) framework. Patients with brain tumors, their proxies, and healthcare providers (HCPs) were asked to rate each survey item on relevance. An item was considered a relevant issue if ≥25% of the patients, proxies, or ≥50% of the HCPs considered that item to be an issue. Next, all items in the identified PRO measures were linked to ICF and relevant items in the survey, and the percentage of content coverage was calculated. Results In total, 114 patients, 71 proxies, and 65 HCPs from different countries completed the survey. Fifty-six of 148 (37.8%) items in the survey were considered relevant. The most important aspects mentioned by both patients and proxies were difficulty concentrating, difficulty remembering, multitasking, and handling stress. Depending on the definition, between 35% and 49% of PRO measures were considered to have sufficient content validity (≥80% coverage). Conclusion The content validity was insufficient in more than half of the identified PRO measures, particularly multidimensional measures. Future research should investigate whether different approaches to PRO assessment better meet the needs of all stakeholders.
Zongertinib in Previously Treated <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Authors: John V. Heymach, Gerrina Ruiter, Myung-Ju Ahn, Nicolas Girard, Egbert F. Smit, David Planchard, Yi-Long Wu, Byoung Chul Cho, Noboru Yamamoto, Joshua K. Sabari, Yanqiu Zhao, Hai-Yan Tu, Kiyotaka Yoh, Ernest Nadal, Behbood Sadrolhefazi, Maren Rohrbacher, Ute von Wangenheim, Sabina Eigenbrod-Giese, Jon Zugazagoitia
Journal: New England Journal of Medicine (2025)

Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor that has been shown to have efficacy in persons with advanced or metastatic solid tumors with HER2 alterations in a phase 1 study. We evaluated zongertinib in a multicohort, phase 1a-1b trial involving patients with advanced or metastatic HER2-mutant NSCLC. Here we report the primary analysis of zongertinib in previously treated patients: those with tumors harboring a mutation in the tyrosine kinase domain (cohort 1), those with tumors harboring a mutation in the tyrosine kinase domain previously treated with a HER2-directed antibody-drug conjugate (cohort 5), and those with tumors harboring a non-tyrosine kinase domain mutation (cohort 3). In cohort 1, patients were initially randomly assigned to receive zongertinib at a dose of 120 mg or 240 mg once daily. Patients in cohorts 5 and 3 initially received 240 mg daily. After an interim analysis of data from cohort 1, subsequently recruited patients across all cohorts received zongertinib at a dose of 120 mg. The primary end point was an objective response assessed by blinded independent central review (cohorts 1 and 5) or by investigator review (cohort 3). Secondary end points included the duration of response and progression-free survival. In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg. At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0.001 against a ≤30% benchmark) had a confirmed objective response; the median duration of response was 14.1 months (95% CI, 6.9 to not evaluable), and the median progression-free survival was 12.4 months (95% CI, 8.2 to not evaluable). Grade 3 or higher drug-related adverse events occurred in 13 patients (17%). In cohort 5 (31 patients), 48% of the patients (95% CI, 32 to 65) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 1 patient (3%). In cohort 3 (20 patients), 30% of the patients (95% CI, 15 to 52) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 5 patients (25%). Across all three cohorts, no cases of drug-related interstitial lung disease occurred. Zongertinib showed clinical benefit with mainly low-grade adverse events in patients with previously treated HER2-mutant NSCLC. (Funded by Boehringer Ingelheim; Beamion LUNG-1 ClinicalTrials.gov number, NCT04886804.).
Proactive Mapping and Preventive Ablation Reduce Defibrillator Implantation Rates in Tetralogy of Fallot
Authors: Yoshitaka Kimura, Justin Wallet, Charlotte Brouwer, Jouke P Bokma, Robin A Bertels, Monique R M Jongbloed, Mark G Hazekamp, Nico A Blom, Katja Zeppenfeld
Journal: Journal of the American College of Cardiology (2025)
Single-Cell Resolved Oncogene Co-expression: From Principles to Clinical Impact
Authors: Shruti Sridhar, Allison S.Y. Chan, Anand D. Jeyasekharan
Journal: Blood Cancer Discovery (2025)

Summary: This commentary explores the concept and utility of studying oncogene co-expression at single-cell resolution and its clinical and biological implications. We emphasize the importance of scalable methods, mathematically driven quantification models, and artificial intelligence integration to enhance the clinical utility of this approach.
Correction to: BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension
Authors: Qiujun Yu, Yi-Yin Tai, Ying Tang, Jingsi Zhao, Vinny Negi, Miranda K. Culley, Jyotsna Pilli, Wei Sun, Karin Brugger, Johannes Mayr, Rajeev Saggar, Rajan Saggar, W. Dean Wallace, David J. Ross, Aaron B. Waxman, Stacy G. Wen-dell, Steven J. Mullett, John Sembrat, Mauricio Rojas, Omar F. Khan, James E. Dahlman, Masataka Sugahara, Nobuyuki Kagiyama, Taijyu Satoh, Manling Zhang, Ning Feng, John Gorcsan, Sara O. Vargas, Kathleen J. Haley, Rahul Kumar, Brian B. Graham, Robert Langer, Daniel G. Anderson, Bing Wang, Sruti Shiva, Thomas Bertero, Stephen Y. Chan
Journal: Circulation (2025)
Interplay Between Epicardial Adipose Tissue and Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction
Authors: Shiro Nakamori, Taku Omori, Naoki Fujimoto, Masaki Ishida, Yasutaka Ichikawa, Kakuya Kitagawa, Hajime Sakuma, Kaoru Dohi
Journal: Circulation (2025)
Correction to: Core Components of Cardiac Rehabilitation Programs: 2024 Update: A Scientific Statement From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation
Authors: Todd M. Brown, Quinn R. Pack, Ellen Aberegg, LaPrincess C. Brewer, Yvonne R. Ford, Daniel E. Forman, Emily C. Gathright, Sherrie Khadanga, Cemal Ozemek, Randal J. Thomas
Journal: Circulation (2025)